Piper Sandler analyst David Amsellem downgraded Horizon Therapeutics (HZNP) to Neutral from Overweight with a price target of $116.50, up from $110, after Horizon announced a deal to be acquired by Amgen (AMGN) for $116.50 per share.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HZNP:
- Horizon Therapeutics downgraded to Hold from Buy at Stifel
- Unusually active option classes on open December 12th
- Amgen (NASDAQ:AMGN) to Buy Horizon for $27.8B; HZNP Stock Rallies
- Amgen to acquire Horizon Therapeutics for $116.50 per share in cash
- Amgen nears deal to acquire Horizon Therapeutics, WSJ reports